Short summary

The aim of the registry is to generate real-world evidence to ensure evidence-based treatment guidelines of the highest quality. Based on retrospective evaluation of hospital files, we collect key clinical data on all patients with melanoma who are candidates for medical therapy in Denmark. Thus, the database enables us to investigate how real-world treatment efficacy and safety compare with available evidence from clinical trials, which have formed the basis of our current treatment strategies.

Rationale

The database constitutes a significant platform for clinical research on the medical treatment of metastatic melanoma patients.

Description of the cohort

Data on pts with distant or regional metastatic melanoma admitted for treatment in one of the four centers treating melanoma patients have since 2011 been included in the database.

Data and biological material

We collect baseline clinical and paraclinical data, combined with data on the effecacy of the treatment offered to the patients

Collaborating researchers and departments

Dept of Oncology, Ålborg University Hospital

• Adam Luczak

Dept of Oncology, Århus University Hospital

• Henrik Schmidt
• Rasmus Friis
• Louise Guldbrandt

Dept of Oncology, Herlev University Hospital

• Inge Marie Svane
• Eva Ellebæk
• Marco Donia

Dept of Oncology, Odense University Hospital

• Lars Bastholt
• Christina Ruhlmann

Publications associated with the project

Donia M, Kimper-Karl ML, Høyer KL, Bastholt L, Schmidt H, Svane IM. The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials. European Journal of Cancer. 2017;74:89-95.

Donia M, Ellebaek E, Øllegaard TH, Duval L, Aaby JB, Hoejberg L, Køhler UH, Schmidt H, Bastholt L, Svane IM. The real-world impact of modern treatments on the survival of patients with metastatic melanoma. European Journal of Cancer. 2019;108:25-32.

Bastholt L, Svane IM, Bjerregaard JK, Herrstedt J, Hróbjartsson A, Schmidt H. High-dose interleukin-2 and interferon as first-line immunotherapy for metastatic melanoma: long-term follow-up in a large unselected Danish patient cohort. European Journal of Cancer. 2019;115:61-7

Ellebaek E, Bastholt L, Schmidt H, Svane IM, Donia M. The real-world outcome of metastatic melanoma: Unknown primary vs. known cutaneous. Int J Cancer. 2019;145(11):3173-4.

Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, Johansson I, Phung B, Harbst K, Vallon-Christersson J, van Schoiack A, Lovgren K, Warren S, Jirstrom K, Olsson H, Pietras K, Ingvar C, Isaksson K, Schadendorf D, Schmidt H, Bastholt L, Carneiro A, Wargo JA, Svane IM, Jonsson G. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577(7791):561

Ellebaek E, Svane IM, Schmidt H, Haslund CA, Donia M, Hoejberg L, Ruhlmann C, Guldbrandt LM, Køhler UH, Bastholt L. The Danish metastatic melanoma database (DAMMED): A nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients. Cancer Epidemiol. 2021;73:101943.

Ellebaek E, Schina A, Andersen R, Hendel HW, Svane IM, Donia M. Clinical value of routine [18F]2-fluoro-2-deoxy-d-glucose positron emission tomography scans as a decision tool for early immunotherapy discontinuation in advanced melanoma. Int J Cancer. 2022.

Pedersen S, Holmstroem RB, von Heymann A, Tolstrup LK, Madsen K, Petersen MA, Haslund CA, Ruhlmann CH, Schmidt H, Johansen C, Svane IM, Ellebaek E. Quality of life and mental health in real-world patients with resected stage III/IV melanoma receiving adjuvant immunotherapy. Acta Oncologica. 2023;62(1):62-9.

Fink M, Vittrup AS, Bastholt L, Svane IM, Donia M, Luczak AA, Ruhlmann CH, Guldbrandt LM, Koehler UH, Winther ML, Ellebaek E, Haslund CA, Schmidt H. Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study. Cancers. 2021;13(21):5550.

Andersen JAS, Spatzek AD, Vilstrup MH, Grupe P, Hess S, Holdgaard PC, Bastholt L, Gerke O, Hildebrandt MG. The diagnostic accuracy and clinical impact of FDG-PET/CT follow-up for patients on adjuvant immunotherapy for high-risk malignant melanoma. European Journal of Nuclear Medicine and Molecular Imaging. 2022:1-10